Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

CVS Health Corporation is a vertically integrated healthcare corporation in the United States. The company owns a leading ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

CVS Health® (NYSE: CVS) is actively supporting its customers, members, provider partners and colleagues as they respond to the California wildfires. The company prioritizes the health and safety of ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.